Document Detail

Accidental shortening time of high dose methotrexate infusion: case report and literature review.
MedLine Citation:
PMID:  23587592     Owner:  NLM     Status:  Publisher    
Methotrexate (MTX) is a folic acid antagonist used at high-dose intravenously on 24 hours (24h) in the treatment of the acute lymphoblastic leukemia (ALL). To prevent potential toxicity, MTX is usually administered following the application of preventive measures. We report a case of an accidental shortening time for high dose MTX infusion and a literature review of accidental intoxications by the MTX. This case illustrates the importance of the respect of MTX high dose infusion time and the major role played by the therapeutic drug monitoring.
Rim Charfi; Issam Salouage; Sameh Trabelsi; Mohamed Zarrouk; Emna Gaïes; Nadia Jebabli; Balkis Meddeb; Mohamed Lakhal; Anis Klouz
Publication Detail:
Journal Detail:
Title:  Annales de biologie clinique     Volume:  71     ISSN:  1950-6112     ISO Abbreviation:  Ann. Biol. Clin. (Paris)     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-4-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2984690R     Medline TA:  Ann Biol Clin (Paris)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  219-222     Citation Subset:  -    
Service de pharmacologie clinique, Centre national de pharmacovigilance de Tunis, Tunisie, Faculté de médecine de Tunis, Université de Tunis El Manar, Tunisie.
Vernacular Title:
Raccourcissement accidentel du temps de perfusion de méthotrexate à haute dose : cas clinique et revue de la littérature<!--<RunningTitle>Perfusion de méthotrexate à haute dose : cas clinique et revue de la littérature</RunningTitle>-->
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A case report of Streptococcus pneumoniae-induced hemolytic uremic syndrome: appropriate transfusion...
Next Document:  Identification of a cystic fibrosis mutation W19X in Tunisia.